Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | G6PD | P11413 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL822300 | 0.73 | GSK3A (0.31) | — | |
| SCHEMBL8985675 | 0.73 | CYP2C19 (0.31) | — | |
| SCHEMBL24872285 | 0.72 | DNMT1 (0.36) | DNMT1DDAH1NSD2G6PDKEAP1 | |
| SCHEMBL3443427 | 0.72 | DNMT1 (0.36) | DNMT1DDAH1NSD2G6PDKEAP1 | |
| SCHEMBL21772524 | 0.72 | DNMT1 (0.36) | DNMT1DDAH1NSD2G6PDKEAP1 | |
| SCHEMBL43717 | 0.68 | CSNK2A2 (0.48) | DNMT1DDAH1NSD2G6PDKEAP1 | |
| SCHEMBL8989652 | 0.68 | GSK3A (0.31) | — | |
| SCHEMBL1955692 | 0.68 | GSK3A (0.31) | — | |
| SCHEMBL3813596 | 0.68 | MGLL (0.32) | — | |
| SCHEMBL932564 | 0.68 | CSNK2A2 (0.48) | DNMT1DDAH1NSD2G6PDKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3620177-A1 | MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER | Baxalta GmbH (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-20190160178-A1 | MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-30 | — | — | US | disclosed |
| EP-3437661-A1 | MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER | Baxalta GmbH (CH) | 2019-02-06 | — | — | EP | disclosed |
| EP-2349342-B1 | MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER | Baxalta GmbH (CH) | 2018-06-27 | — | — | EP | disclosed |
| US-20170227557-A1 | METHOD AND COMPOSITIONS FOR SPECIFICALLY DETECTING PHYSIOLOGICALLY ACCEPTABLE POLYMER MOLECULES | BAXTER HEALTHCARE SA (CH) | 2017-08-10 | — | — | US | disclosed |
| US-9547016-B2 | Method and compositions for specifically detecting physiologically acceptable polymer molecules | BAXALTA INCORPORATED (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160199503-A1 | MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER | BAXTER INTERNATIONAL INC. | 2016-07-14 | — | — | US | disclosed |
| US-9274122-B2 | Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation) | BAXALTA INCORPORATED (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2606074-B1 | CURABLE POLYMER MIXTURE | BYK CHEMIE GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-20140051094-A1 | Method and Compositions for Specifically Detecting Physiologically Acceptable Polymer Molecules | BAXTER HEALTHCARE SA (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20040242854-A1 | Chemical capture reagent | GE HEALTHCARE UK LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
| WO-2004074345-A2 | CARBONATE ESTERS OF POLYETHYLENE GLYCOL ACTIVATED BY MEANS OF OXALATE ESTERS | PHARMACIA CORPORATION (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040162388-A1 | Activated polyethylene glycol esters | PHARMACIA CORPORATION | 2004-08-19 | — | — | US | disclosed |
| WO-2004051270-A2 | LABELING METHODOLOGY COMPRISING OLIGOPEPTIDES | NOVARTIS AG (CH) | 2004-06-17 | — | — | WO | disclosed |
| EP-1402268-A2 | CHEMICAL CAPTURE REAGENT | Amersham Biosciences UK Limited (GB) | 2004-03-31 | — | — | EP | disclosed |
| US-20040029207-A1 | Compositions and methods for detecting and quantifying COX-2 activity by lipoamino acid metabolism | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-12 | — | — | US | disclosed |
| WO-2003014699-A2 | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING COX-2 ACTIVITY BY LIPOAMINO ACID METABOLISM | VANDERBILT UNIVERSITY (US) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003005026-A2 | CHEMICAL CAPTURE REAGENT | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2003-01-16 | — | — | WO | disclosed |
| JP-2002256025-A | METHOD FOR PRODUCING AQUEOUS POWDER SLURRY COMPOSITION | DAINIPPON INK & CHEM INC | 2002-09-11 | — | — | JP | disclosed |
| EP-0847991-A1 | Method for the preparation of N-(carboxyalkyl) imides | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162388-A1 | Activated polyethylene glycol esters | ACP1, FGF23, ACP3 | DNMT1 4882/4885DDAH1 2879/4885NSD2 4850/4885 |
| US-20040242854-A1 | Chemical capture reagent | SPPL2B, PRXL2A, PLG | DNMT1 4776/4885DDAH1 1124/4885NSD2 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.